期刊
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
卷 2022, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2022/5122448
关键词
-
类别
资金
- National Nature Science Foundation of China [82160825]
- Natural Science Foundation of Guizhou Province [QKH-J (2020) 1Y377]
- Zunyi Science and Technology Project [ZSKHHZZ(2020)85]
- Science and Technology Program of Guizhou Province [QKPTRC(2019)-024]
- Guangdong Provincial Key Laboratory of Functional Substances in Medicinal Edible Resources and Healthcare Products [2021B1212040015, GPKLFSHP202101]
- Scientific Projects of Key Disciplines in Guangdong Province [2021ZDJS042]
- National Science Foundation of Jiangsu Province of China [BK20201477]
- Major Program of Natural Science Foundation of the Higher Education Institutions of Jiangsu Province of China [20KJA360006]
Lung cancer is a major cause of cancer-related death globally for both men and women. Non-small-cell lung cancer (NSCLC), which is difficult to control with conventional therapy, has a poor prognosis. This study found that ononin, an isoflavone glycoside extracted from Astragali Radix, can inhibit NSCLC progression and promote apoptosis when combined with paclitaxel (PTX). The combination treatment showed enhanced antitumor effects by inhibiting cell proliferation through the PI3K/Akt/mTOR signaling pathways and reducing PTX-induced liver and kidney damage.
Lung cancer is a leading global cause of cancer-related death in both males and females. Non-small-cell lung cancer (NSCLC) is the most commonly diagnosed cancer type that can be difficult to control with conventional chemotherapeutic and surgical approaches resulting in a poor prognosis. Paclitaxel (PTX) is a commonly used chemotherapeutic drug for NSCLC, which can cause tissue injury in healthy cells and affect the quality of life in patients with cancer. In order to treat NSCLC, alternative medications with minimal or no side effects are highly needed. Ononin is an isoflavone glycoside extracted from Astragali Radix (AR) that has various pharmacological activities. Therefore, this study investigated whether ononin inhibits NSCLC progression and promotes apoptosis synergistically with PTX both in vitro and in vivo. Antitumorigenic properties of ononin were determined by MTT assay, colony formation assay, migratory capacity, and apoptotic marker expression in A549 and HCC827 cells. The combination of ononin with PTX increased the expression of apoptotic markers and ROS generation and inhibited cell proliferation through the PI3K/Akt/mTOR signaling pathways. Furthermore, ononin prevented the translocation of NF-kappa B from cytosol to the nucleus. Also, we used the xenograft NSCLC mice model to confirm the in vivo antitumorigenic efficacies of ononin by reduction of CD34 and Ki67 expressions. Based on the histological analysis, the cotreatment of PTX and ononin reduced PTX-induced liver and kidney damage. Overall, our findings suggested that the therapeutic index of PTX-based chemotherapy could be improved by reducing toxicity with increasing antitumor capabilities when combined with ononin.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据